PharmaCyte Biotech Inc (PMCB)

[tjclark0551]

1234, IR's response to me about CC

Investor Relations <[e-mail]>

May 5 at 6:32 PM
Dear Mr.,
Please accept our apologies for being so tardy in responding to your email. We just discovered it in our junk mail.
Long ago our CEO said we planned to do quarterly conference calls. However, the subject of deferring those in favor of press release updates was addressed by our CEO in a press release dated May 30, 2018. Here is a link to that press release: https://pharmacyte.com/pharmacyte-biotech-ceo-cso-interviewed-ind-planned-clinical-trial-pancreatic-cancer-cro/
Everyone at PharmaCyte is fully engaged trying to bring its therapy for pancreatic cancer to the point of an IND submission to the FDA. We don’t want to provide an update on every new development we sometimes face daily. The market will react accordingly, even though the issue may have been resolved the next day or even before the update is published.
We will continue to conduct business responsibly. When we have material information to report, we will do so as we always have – publish a press release. We should be publishing an update this coming week.
Thank you for your continued support of the Company.
Investor Relations
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92630
O 917.595.2856 | F 917.595.2851